Value Will Pave The Way For Innovative Brands, Pfizer’s Germano Says
Executive Summary
Global Innovative Pharma Business President Geno Germano sat down with “The Pink Sheet” to discuss growth strategy, M&A and Pfizer’s increasing focus on value in a changing health care world.
You may also be interested in...
Pfizer Gets Palbociclib To NDA Finish Line On Phase II Data
Pfizer finished a rolling NDA for the high-profile breast cancer drug, the first-in-class CDK-4/6 inhibitor. Whether or not FDA will agree Phase II data results from the PALOMA-1 trial are sufficient to grant accelerated approval remains to be seen.
Sanofi Steps Up To Lend A Hand Producing Pfizer/BioNTech's COVID-19 Vaccine In Europe
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
J&J Forecasts Strong Pharma Growth In 2021, But No COVID-19 Vaccine Update
Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: